Cargando…
MiR-205 Is Progressively Down-Regulated in Lymph Node Metastasis but Fails as a Prognostic Biomarker in High-Risk Prostate Cancer
The treatment of high-risk prostate cancer (HRPCa) is a tremendous challenge for uro-oncologists. The identification of predictive moleculobiological markers allowing risk assessment of lymph node metastasis and systemic progression is essential in establishing effective treatment. In the current st...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Molecular Diversity Preservation International (MDPI)
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3856012/ https://www.ncbi.nlm.nih.gov/pubmed/24173237 http://dx.doi.org/10.3390/ijms141121414 |
_version_ | 1782294999426138112 |
---|---|
author | Kalogirou, Charis Spahn, Martin Krebs, Markus Joniau, Steven Lerut, Evelyne Burger, Maximilian Scholz, Claus-Jürgen Kneitz, Susanne Riedmiller, Hubertus Kneitz, Burkhard |
author_facet | Kalogirou, Charis Spahn, Martin Krebs, Markus Joniau, Steven Lerut, Evelyne Burger, Maximilian Scholz, Claus-Jürgen Kneitz, Susanne Riedmiller, Hubertus Kneitz, Burkhard |
author_sort | Kalogirou, Charis |
collection | PubMed |
description | The treatment of high-risk prostate cancer (HRPCa) is a tremendous challenge for uro-oncologists. The identification of predictive moleculobiological markers allowing risk assessment of lymph node metastasis and systemic progression is essential in establishing effective treatment. In the current study, we investigate the prognostic potential of miR-205 in HRPCa study and validation cohorts, setting defined clinical endpoints for both. We demonstrate miR-205 to be significantly down-regulated in over 70% of the HRPCa samples analysed and that reconstitution of miR-205 causes inhibition of proliferation and invasiveness in prostate cancer (PCa) cell lines. Additionally, miR-205 is increasingly down-regulated in lymph node metastases compared to the primary tumour indicating that miR-205 plays a role in migration of PCa cells from the original location into extraprostatic tissue. Nevertheless, down-regulation of miR-205 in primary PCa was not correlated to the synchronous presence of metastasis and failed to predict the outcome for HRPCa patients. Moreover, we found a tendency for miR-205 up-regulation to correlate with an adverse outcome of PCa patients suggesting a pivotal role of miR-205 in tumourigenesis. Overall, we showed that miR-205 is involved in the development and metastasis of PCa, but failed to work as a useful clinical biomarker in HRPCa. These findings might have implications for the use of miR-205 as a prognostic or therapeutic target in HRPCa. |
format | Online Article Text |
id | pubmed-3856012 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Molecular Diversity Preservation International (MDPI) |
record_format | MEDLINE/PubMed |
spelling | pubmed-38560122013-12-09 MiR-205 Is Progressively Down-Regulated in Lymph Node Metastasis but Fails as a Prognostic Biomarker in High-Risk Prostate Cancer Kalogirou, Charis Spahn, Martin Krebs, Markus Joniau, Steven Lerut, Evelyne Burger, Maximilian Scholz, Claus-Jürgen Kneitz, Susanne Riedmiller, Hubertus Kneitz, Burkhard Int J Mol Sci Article The treatment of high-risk prostate cancer (HRPCa) is a tremendous challenge for uro-oncologists. The identification of predictive moleculobiological markers allowing risk assessment of lymph node metastasis and systemic progression is essential in establishing effective treatment. In the current study, we investigate the prognostic potential of miR-205 in HRPCa study and validation cohorts, setting defined clinical endpoints for both. We demonstrate miR-205 to be significantly down-regulated in over 70% of the HRPCa samples analysed and that reconstitution of miR-205 causes inhibition of proliferation and invasiveness in prostate cancer (PCa) cell lines. Additionally, miR-205 is increasingly down-regulated in lymph node metastases compared to the primary tumour indicating that miR-205 plays a role in migration of PCa cells from the original location into extraprostatic tissue. Nevertheless, down-regulation of miR-205 in primary PCa was not correlated to the synchronous presence of metastasis and failed to predict the outcome for HRPCa patients. Moreover, we found a tendency for miR-205 up-regulation to correlate with an adverse outcome of PCa patients suggesting a pivotal role of miR-205 in tumourigenesis. Overall, we showed that miR-205 is involved in the development and metastasis of PCa, but failed to work as a useful clinical biomarker in HRPCa. These findings might have implications for the use of miR-205 as a prognostic or therapeutic target in HRPCa. Molecular Diversity Preservation International (MDPI) 2013-10-29 /pmc/articles/PMC3856012/ /pubmed/24173237 http://dx.doi.org/10.3390/ijms141121414 Text en © 2013 by the authors; licensee MDPI, Basel, Switzerland http://creativecommons.org/licenses/by/3.0/ This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/). |
spellingShingle | Article Kalogirou, Charis Spahn, Martin Krebs, Markus Joniau, Steven Lerut, Evelyne Burger, Maximilian Scholz, Claus-Jürgen Kneitz, Susanne Riedmiller, Hubertus Kneitz, Burkhard MiR-205 Is Progressively Down-Regulated in Lymph Node Metastasis but Fails as a Prognostic Biomarker in High-Risk Prostate Cancer |
title | MiR-205 Is Progressively Down-Regulated in Lymph Node Metastasis but Fails as a Prognostic Biomarker in High-Risk Prostate Cancer |
title_full | MiR-205 Is Progressively Down-Regulated in Lymph Node Metastasis but Fails as a Prognostic Biomarker in High-Risk Prostate Cancer |
title_fullStr | MiR-205 Is Progressively Down-Regulated in Lymph Node Metastasis but Fails as a Prognostic Biomarker in High-Risk Prostate Cancer |
title_full_unstemmed | MiR-205 Is Progressively Down-Regulated in Lymph Node Metastasis but Fails as a Prognostic Biomarker in High-Risk Prostate Cancer |
title_short | MiR-205 Is Progressively Down-Regulated in Lymph Node Metastasis but Fails as a Prognostic Biomarker in High-Risk Prostate Cancer |
title_sort | mir-205 is progressively down-regulated in lymph node metastasis but fails as a prognostic biomarker in high-risk prostate cancer |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3856012/ https://www.ncbi.nlm.nih.gov/pubmed/24173237 http://dx.doi.org/10.3390/ijms141121414 |
work_keys_str_mv | AT kalogiroucharis mir205isprogressivelydownregulatedinlymphnodemetastasisbutfailsasaprognosticbiomarkerinhighriskprostatecancer AT spahnmartin mir205isprogressivelydownregulatedinlymphnodemetastasisbutfailsasaprognosticbiomarkerinhighriskprostatecancer AT krebsmarkus mir205isprogressivelydownregulatedinlymphnodemetastasisbutfailsasaprognosticbiomarkerinhighriskprostatecancer AT joniausteven mir205isprogressivelydownregulatedinlymphnodemetastasisbutfailsasaprognosticbiomarkerinhighriskprostatecancer AT lerutevelyne mir205isprogressivelydownregulatedinlymphnodemetastasisbutfailsasaprognosticbiomarkerinhighriskprostatecancer AT burgermaximilian mir205isprogressivelydownregulatedinlymphnodemetastasisbutfailsasaprognosticbiomarkerinhighriskprostatecancer AT scholzclausjurgen mir205isprogressivelydownregulatedinlymphnodemetastasisbutfailsasaprognosticbiomarkerinhighriskprostatecancer AT kneitzsusanne mir205isprogressivelydownregulatedinlymphnodemetastasisbutfailsasaprognosticbiomarkerinhighriskprostatecancer AT riedmillerhubertus mir205isprogressivelydownregulatedinlymphnodemetastasisbutfailsasaprognosticbiomarkerinhighriskprostatecancer AT kneitzburkhard mir205isprogressivelydownregulatedinlymphnodemetastasisbutfailsasaprognosticbiomarkerinhighriskprostatecancer |